Back to list

NEFECON for IgA Nephropathy

University of North Carolina at Chapel Hill


Description

This study is for patients diagnosed with Primary IgA Nephropathy, a kidney disease . it involves research and is conducted to determine the efficacy and safety of a drug called Nefecon (with the active ingredient, budesonide) The purpose of the study is to look at: • How well Nefecon works for the treatment of kidney disease and more specific for patients with the disease "primary immunoglobulin A nephropathy", called IgAN; and • How safe and effective Nefecon is compared to placebo.


Keywords:

Kidneys


Category:

Drug or Biologic
Phase:3

Qualifications

 


Age
18 - 99 years


Gender
Any


Study Population

adult patients with IgA nephropathy


Investigator

Amy Mottl
Clinical Associate Professor
Medicine-Nephrology

For questions, contact:

Anne Froment
anne_froment@med.unc.edu
(919) 445-2622


Recruitment Period End

June 30, 2020

Location

Primary Location
Clinical and Translational Research Center
Burnett-Womack Building, 160 Dental Cir, Chapel Hill, NC 27514, USA

Study Qualifications

Gender Any

Age Range 18 - 99 years

Participant qualification(s) -biopsy of the kidney showing IgA nephropathy done in the last 5 years -protein in the urine

Not eligible if: -transplant (or on the transplant list) -dialysis -type 1 diabetes -heart problems -recent cancer -pregnant

Number of Visits

    » 17 In person visit(s)

    17 clinic visits

    » 17 Remote visit(s)

    17 phone calls

Participation Period

6 years

Compensation

$30/visit

By clicking I am interested, your contact information will be sent to the researcher/study coordinator for this study. The coordinator will respond by email with additional information on how to proceed.